GNHAF News and Press, Vifor Pharma AG From 03/03/21

The following slide deck was published by Vifor Pharma AG in conjunction with their 2020 Q4 earnings call. For further details see: Vifor Pharma AG 2020 Q4 - Results - Earnings Call Presentation

Complete results from a Phase 4 clinical trial, AFFIRM-AHF, evaluating Vifor Pharma's ([[GNHAF]]) Ferinject (intravenous ferric carboxymaltose) in acute heart failure patients ((HF)) with iron deficiency showed significantly fewer HF hospitalizations compared to placebo. The data were pr...

Vifor Pharma (GNHAF) and Angion Biomedica have signed a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function ((DGF)) and cardiac surgery-associated acute kidney injury (CSA-AKI).ANG-3777 was engineered to mimic the biologi...

Cara Therapeutics (CARA) jumps 12% in premarket on moderate volume, after announcing a profit-sharing deal with Vifor Pharma (GNHAF), for the commercialization of intravenous ((IV)) Korsuva as a treatment of chronic kidney disease-associated pruritus in the U.S. dialysis market...

The following slide deck was published by Vifor Pharma AG in conjunction with this event. For further details see: Vifor Pharma (GNHAF) Investor Presentation - Slideshow

Vifor Pharma ( OTCPK:GNHAF ) has announced changes to its management. More news on: Vifor Pharma AG, Healthcare stocks news, Read more ...

Vifor Pharma AG ( OTCPK:GNHAF ): 1H Non-GAAP EPS of CHF2.11. More news on: Vifor Pharma AG, Vifor Pharma AG, Earnings news and commentary, Healthcare stocks news, Read more ...

Vifor Pharma AG ( OTCPK:GNHAF ): FY Non-GAAP EPS of CFH4.16. More news on: Vifor Pharma AG, Vifor Pharma AG, Earnings news and commentary, Healthcare stocks news, Read more ...

The following slide deck was published by Vifor Pharma AG ADR in conjunction with their 2018 Q2 earnings Read more ...